Dyne Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dyne Therapeutics (DYN).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

14Buy

1Hold

1Sell

Consensus RatingOutperform# Analysts17Avg. Consensus PT$37Upside to Avg. PT+121.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Oppenheimer	Kostas Biliouris	Downgrade	Outperform→Perform	$40→$15
Sep 30, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Sep 30, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$50→$32
Sep 29, 2026	Piper Sandler	Edward Tenthoff	Maintained	Overweight	$47
Sep 9, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$45→$36
Sep 9, 2026	JP Morgan	Tessa Romero	Downgrade	Neutral→Underweight	$17→$10
Sep 9, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$35→$30
Sep 9, 2026	Baird	Brian Skorney	PT Cut	Outperform	$30→$26
Jul 31, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$47→$45
Jul 30, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$30→$35
Jul 23, 2026	Cantor Fitzgerald	Eric Schmidt	Initiate	Overweight	—
Jun 26, 2026	TD Cowen	Joseph Thome	Initiate	Buy	—
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$34→$33
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$23→$24
Mar 9, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$50→$47
Mar 3, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$60→$50
Jan 20, 2026	JP Morgan	Tessa Romero	PT Cut	Neutral	$17→$16
Dec 15, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$38→$36

Analyst Ratings News

PRO
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15

Oppenheimer analyst Kostas Biliouris downgrades Dyne Therapeutics (NASDAQ:DYN) from Outperform to Perform and lowers the price target from $40 to $15.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.

Benzinga Newsdesk

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15

PROHC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PROPiper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PROBaird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

PRO
Oppenheimer Downgrades Dyne Therapeutics to Perform, Lowers Price Target to $15

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26